Psychodynamic Psychotherapy for PTSD
(RCT of TFPP Trial)
Trial Summary
What is the purpose of this trial?
This trial tests a new talk therapy called TFPP for veterans with PTSD who haven't been helped by current treatments. TFPP helps veterans understand and process their trauma through structured conversations, aiming to improve their overall mental health.
Will I have to stop taking my current medications?
The trial requires participants to be stable on their psychiatric medications for at least 2 months before joining, so you should not stop taking your current medications.
What data supports the effectiveness of the treatment Trauma-Focused Psychodynamic Psychotherapy (TFPP) for PTSD?
Research suggests that Trauma-Focused Psychodynamic Psychotherapy (TFPP) can be effective for PTSD by addressing emotional and psychological issues related to trauma, as seen in studies involving veterans and LGBTQ individuals. This therapy helps patients understand and process their traumatic experiences, which can reduce PTSD symptoms.12345
Is Trauma-Focused Psychodynamic Psychotherapy (TFPP) safe for treating PTSD?
What makes Trauma-Focused Psychodynamic Psychotherapy (TFPP) unique for treating PTSD?
Trauma-Focused Psychodynamic Psychotherapy (TFPP) is unique because it explores the psychological meanings of PTSD symptoms and their relation to traumatic events, focusing on narrative coherence and emotional regulation. It also incorporates identity-related and societal factors, making it particularly beneficial for LGBTQ individuals seeking affirmative care.134910
Research Team
Barbara L Milrod, MD
Principal Investigator
Weill Medical College of Cornell University
Eligibility Criteria
This trial is for Veterans with moderate PTSD (CAPS score >40) who haven't improved after standard VA treatments. They must have stable psychiatric meds for 2 months and a history of not responding well to certain PTSD therapies. It's not for those with severe suicidality, psychosis, bipolar disorder, substance issues that affect participation, or unstable medical conditions.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Trauma-Focused Psychodynamic Psychotherapy (TFPP) or Treatment as Usual (TAU) for PTSD
Follow-up
Participants are monitored for changes in PTSD symptoms and other psychological measures
Treatment Details
Interventions
- TAU (Behavioural Intervention)
- Trauma-Focused Psychodynamic Psychotherapy (TFPP) (Psychodynamic Psychotherapy)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Montefiore Medical Center
Lead Sponsor
Andrew D. Racine
Montefiore Medical Center
Chief Medical Officer since 1992
MD, PhD from New York University; Undergraduate degree from Harvard University
Philip O. Ozuah
Montefiore Medical Center
Chief Executive Officer since 2019
MD, PhD from New York University
Weill Medical College of Cornell University
Lead Sponsor
Dr. Robert Min
Weill Medical College of Cornell University
Chief Executive Officer since 2024
MD, MBA
Dr. Adam R. Stracher
Weill Medical College of Cornell University
Chief Medical Officer since 2024
MD
International Psychoanalytic Association (IPA)
Collaborator
National Center for Advancing Translational Sciences (NCATS)
Collaborator
Dominique C. Pichard
National Center for Advancing Translational Sciences (NCATS)
Chief Medical Officer since 2023
MD
Joni L. Rutter
National Center for Advancing Translational Sciences (NCATS)
Chief Executive Officer since 2022
PhD in Pharmacology
Weill Medical College Clinical Science Translation Center
Collaborator
American Psychoanalytic Association (APsA)
Collaborator
International Psychoanalytic Association
Collaborator
VA New York Harbor Healthcare System
Collaborator
CTSC
Collaborator
American Psychoanalytic Association Fund for Psychoanalytic Research
Collaborator